OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Arterial chemotherapy for hepatocellular carcinoma in China: consensus recommendations
Ming Zhao, Zhi Guo, Yinghua Zou, et al.
Hepatology International (2023) Vol. 18, Iss. 1, pp. 4-31
Closed Access | Times Cited: 21
Ming Zhao, Zhi Guo, Yinghua Zou, et al.
Hepatology International (2023) Vol. 18, Iss. 1, pp. 4-31
Closed Access | Times Cited: 21
Showing 21 citing articles:
Patients with hepatocellular carcinoma extrahepatic metastases can benefit from hepatic arterial infusion chemotherapy combined with lenvatinib plus programmed Death-1 inhibitors
Renguo Guan, Nan Zhang, Min Deng, et al.
International Journal of Surgery (2024)
Open Access | Times Cited: 15
Renguo Guan, Nan Zhang, Min Deng, et al.
International Journal of Surgery (2024)
Open Access | Times Cited: 15
Conversion therapy for advanced hepatocellular carcinoma in the era of precision medicine: Current status, challenges and opportunities
Ming‐Da Wang, Xuejun Xu, Ke‐Chun Wang, et al.
Cancer Science (2024) Vol. 115, Iss. 7, pp. 2159-2169
Open Access | Times Cited: 8
Ming‐Da Wang, Xuejun Xu, Ke‐Chun Wang, et al.
Cancer Science (2024) Vol. 115, Iss. 7, pp. 2159-2169
Open Access | Times Cited: 8
HAIC plus lenvatinib and tislelizumab for advanced hepatocellular carcinoma with Vp4 portal vein invasion
Shuang‐Yan Tang, Feng Shi, Yi Xiao, et al.
Hepatology International (2025)
Closed Access
Shuang‐Yan Tang, Feng Shi, Yi Xiao, et al.
Hepatology International (2025)
Closed Access
Hepatic arterial infusion chemotherapy combined with immune checkpoint inhibitors and molecular targeted therapies for advanced infiltrative hepatocellular carcinoma: a single-center experience
Zizhuo Wang, Songlin Song, Lijie Zhang, et al.
Frontiers in Immunology (2025) Vol. 15
Open Access
Zizhuo Wang, Songlin Song, Lijie Zhang, et al.
Frontiers in Immunology (2025) Vol. 15
Open Access
Prognosis prediction of α-FAtE score for locoregional immunotherapy in hepatocellular carcinoma
Zehao Zheng, Renguo Guan, Rongce Zhao, et al.
Frontiers in Immunology (2025) Vol. 15
Open Access
Zehao Zheng, Renguo Guan, Rongce Zhao, et al.
Frontiers in Immunology (2025) Vol. 15
Open Access
Combining immune checkpoint inhibitors and molecular-targeted agents with hepatic arterial infusion chemotherapy for hepatocellular carcinoma with inferior vena cava and/or right atrium tumor thrombus
Suixing Zhong, Junzhe Yi, Song Chen, et al.
Hepatology International (2025)
Closed Access
Suixing Zhong, Junzhe Yi, Song Chen, et al.
Hepatology International (2025)
Closed Access
Assessment of non-tumor liver parenchyma damage in advanced gastric cancer treatment with transarterial infusion chemotherapy: a study using imaging and hepatic injury indicators
Yifan Jing, Jian Jing, Xiaokang Sun, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access
Yifan Jing, Jian Jing, Xiaokang Sun, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access
A Metrology Informatics Investigation of Conversion Therapy in Hepatocellular Carcinoma: 2014–2023
Qifeng Chen, Xiongying Jiang, Minshan Chen, et al.
Annals of Surgery Open (2025) Vol. 6, Iss. 1, pp. e562-e562
Open Access
Qifeng Chen, Xiongying Jiang, Minshan Chen, et al.
Annals of Surgery Open (2025) Vol. 6, Iss. 1, pp. e562-e562
Open Access
Techniques and status of hepatic arterial infusion chemotherapy for primary hepatobiliary cancers
Kanglian Zheng, Xiaodong Wang
Therapeutic Advances in Medical Oncology (2024) Vol. 16
Open Access | Times Cited: 4
Kanglian Zheng, Xiaodong Wang
Therapeutic Advances in Medical Oncology (2024) Vol. 16
Open Access | Times Cited: 4
Continuous age- and sex-specific reference ranges of liver enzymes in Chinese children and application in pediatric non-alcoholic fatty liver disease
Zhaoyuan Wu, Si-Wei Chi, Liujian Ouyang, et al.
World Journal of Pediatrics (2024) Vol. 20, Iss. 9, pp. 949-956
Closed Access | Times Cited: 2
Zhaoyuan Wu, Si-Wei Chi, Liujian Ouyang, et al.
World Journal of Pediatrics (2024) Vol. 20, Iss. 9, pp. 949-956
Closed Access | Times Cited: 2
Efficacy and safety of HAIC combined with tyrosine kinase inhibitors versus HAIC monotherapy for advanced hepatocellular carcinoma: a multicenter propensity score matching analysis
Miaomiao Yang, Xiongying Jiang, Huan Liu, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 2
Miaomiao Yang, Xiongying Jiang, Huan Liu, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 2
Clinical Therapy: HAIC Combined with Tyrosine Kinase Inhibitors and Programmed Cell Death Protein-1 Inhibitors versus HAIC Alone for Unresectable Hepatocellular Carcinoma
Baokun Liu, Lujun Shen, Wen Liu, et al.
Journal of Hepatocellular Carcinoma (2024) Vol. Volume 11, pp. 1557-1567
Open Access | Times Cited: 2
Baokun Liu, Lujun Shen, Wen Liu, et al.
Journal of Hepatocellular Carcinoma (2024) Vol. Volume 11, pp. 1557-1567
Open Access | Times Cited: 2
Analysis of Adverse Drug Reactions with Oxaliplatin-Based Hepatic Arterial Infusion Chemotherapy
Yanqin Lu, Zhenzhen Zhang, Yanrong Ye
(2024)
Open Access | Times Cited: 1
Yanqin Lu, Zhenzhen Zhang, Yanrong Ye
(2024)
Open Access | Times Cited: 1
Additional Hepatic Arterial Infusion Chemotherapy to Sorafenib Was Cost-Effective for Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis
Qifeng Chen, Xiongying Jiang, Yue Hu, et al.
Journal of Hepatocellular Carcinoma (2024) Vol. Volume 11, pp. 1473-1479
Open Access | Times Cited: 1
Qifeng Chen, Xiongying Jiang, Yue Hu, et al.
Journal of Hepatocellular Carcinoma (2024) Vol. Volume 11, pp. 1473-1479
Open Access | Times Cited: 1
Hepatic arterial infusion of GEMOX plus systemic gemcitabine chemotherapy combined with lenvatinib and PD-1 inhibitor in large unresectable intrahepatic cholangiocarcinoma
Jia-yan Ni, Hongliang Sun, Ge-Fan Guo, et al.
International Immunopharmacology (2024) Vol. 140, pp. 112872-112872
Closed Access | Times Cited: 1
Jia-yan Ni, Hongliang Sun, Ge-Fan Guo, et al.
International Immunopharmacology (2024) Vol. 140, pp. 112872-112872
Closed Access | Times Cited: 1
Current Trends in Hepatocellular Carcinoma Therapies in China
Ying Zhang, Yong Wang, Jin‐He Guo, et al.
Digestive Disease Interventions (2024) Vol. 08, Iss. 03, pp. 173-182
Closed Access | Times Cited: 1
Ying Zhang, Yong Wang, Jin‐He Guo, et al.
Digestive Disease Interventions (2024) Vol. 08, Iss. 03, pp. 173-182
Closed Access | Times Cited: 1
Hepatic Arterial Infusion Chemotherapy for Unresectable HCC: Ready for Primetime?
Qian Yu, Osman Ahmed
Academic Radiology (2024) Vol. 31, Iss. 3, pp. 844-845
Closed Access
Qian Yu, Osman Ahmed
Academic Radiology (2024) Vol. 31, Iss. 3, pp. 844-845
Closed Access
Cost-Effectiveness Analysis of Hepatic Arterial Chemotherapy for Advanced Hepatocellular Carcinoma in China: A Comparative Analysis of HAIC-FO and Sorafenib
Jie Gao, Shu Liu, Shaojun Li, et al.
Medical Science Monitor (2024) Vol. 30
Open Access
Jie Gao, Shu Liu, Shaojun Li, et al.
Medical Science Monitor (2024) Vol. 30
Open Access
Hepatic arterial infusion therapy for advanced hepatocellular carcinoma after systemic treatment failure: A treatment dilemma–Authors' reply
Junzhe Yi, Ning Lyu, Ming Zhao
Hepatology Research (2024) Vol. 54, Iss. 12, pp. 1236-1237
Closed Access
Junzhe Yi, Ning Lyu, Ming Zhao
Hepatology Research (2024) Vol. 54, Iss. 12, pp. 1236-1237
Closed Access
Progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma
Tong Liu, Guorui Meng, Shihui Ma, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access
Tong Liu, Guorui Meng, Shihui Ma, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access
Efficacy and safety of HAIC-FOLFOX plus tyrosine kinase inhibitors and immune checkpoint inhibitors as first-line treatment for unresectable advanced hepatocellular carcinoma: A systematic review and meta-analysis
Peng Jiang, Chao Chen, Jing Tian, et al.
Academic Radiology (2024)
Open Access
Peng Jiang, Chao Chen, Jing Tian, et al.
Academic Radiology (2024)
Open Access
Advanced hepatocellular carcinoma treatment strategies: Are transarterial approaches leading the way?
Stefan Patauner, Giovanni Scotton, Francesca Notte, et al.
World Journal of Gastrointestinal Oncology (2024) Vol. 17, Iss. 1
Closed Access
Stefan Patauner, Giovanni Scotton, Francesca Notte, et al.
World Journal of Gastrointestinal Oncology (2024) Vol. 17, Iss. 1
Closed Access
